SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are sharply divided over a tokenized crypto asset claiming to represent SpaceX shares, with many warning it is a deceptive scheme unrelated to the company. While the community remains highly skeptical of these digital tokens, genuine excitement is building around the anticipated public listing of the space giant, sparking intense debate over valuations, sector competition, and the risks of falling for speculative pre-IPO hype.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

FARTCOIN is capturing significant community attention as traders debate its potential for a rebound and speculate on its relationship with other meme coins like $UPDOG. While some investors are actively buying the dip, discussion remains polarized between those anticipating a major breakout and others who are skeptical of the token's long-term sustainability.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as the community debates its long-term viability amid stagnant price action and anticipation surrounding the CLARITY Act's impact on crypto payment regulation. While some investors are aggressively accumulating tokens on the expectation of institutional adoption, others express deep frustration over the lack of transparency, declining market value, and the project's perceived inability to move in lockstep with the broader market.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is attracting significant community attention due to its focus on decentralized infrastructure, including sovereign cloud initiatives and AI-integrated applications that aim to bypass traditional tech giants. While some investors remain cautious about long-term price performance and market volatility, others are actively accumulating based on the project's ongoing technical developments and potential for real-world utility.

Tidal Trust III - VistaShares Electrification Supercycle ETF

VistaShares Electrification Supercycle® ETF

Investors are increasingly bullish on this electrification-focused ETF, viewing it as a strategic play on the rising demand for power infrastructure driven by the rapid expansion of AI and EV sectors. The community is highlighting the fund's potential to capture growth within the energy supply chain, often grouping it with other high-growth tech and infrastructure ETFs as a core portfolio holding.

Qorvo, Inc. provides semiconductor solutions for RF and power. The firm combines product and technology leadership, systems-level expertise, and global manufacturing scale to quickly solve its customers' most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including consumer electronics, smart home/IoT, automotive, EVs, battery-powered appliances, network infrastructure, healthcare, and aerospace/defense. It operates through the following segments: High Performance Analog (HPA), Connectivity and Sensors Group (CSG), and Advanced Cellular Group (ACG). The HPA segment supplies RF and power management solutions for infrastructure, defense and aerospace, automotive power, and other markets. The CSG segment supplies connectivity and sensor components and systems featuring multiple technologies such as UWB, Matter, Bluetooth Low Energy, Zigbee, Thread, Wi-Fi, cellular IoT and MEMS-/BAW-based sensors. The ACG segment supplies cellular RF solutions for smartphones, wearables, laptops, tablets, and various other devices. The company was formed following the merger of RF Micro Devices, founded in 2015, and TriQuint Semiconductor, incorporated in 1981. It is headquartered in Greensboro, NC.

Qorvo Inc

Qorvo is trending following a series of analyst downgrades that highlight concerns over handset market saturation and the company's heavy reliance on smartphone demand. Market participants are actively debating the long-term impact of its pending merger with Skyworks and the potential for structural headwinds in the RF semiconductor sector.

BENQI is a decentralized non-custodial liquidity market protocol, built on Avalanche. The protocol enables users to effortlessly lend, borrow, and earn interest with their digital assets. Depositors providing liquidity to the protocol may earn passive income, while borrowers are able to borrow in an over-collateralized manner.

Benqi Finance

Benqi Finance is trending as the community debates its potential for a breakout, driven by its status as a high-TVL project on the Avalanche ecosystem and anticipation surrounding real-world asset (RWA) tokenization. While some investors are aggressively accumulating, citing attractive long-term metrics and a fully unlocked supply, others express frustration with recent price volatility and slow market movement.

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics is currently in focus as investors await clarity following a recent Complete Response Letter for its lead phosphate binder candidate, with the company actively coordinating with the FDA to resolve manufacturing deficiencies. Community discussion remains heavily centered on the upcoming July 14th virtual conference participation and the potential for a rapid regulatory re-submission path that could de-risk the investment thesis ahead of a commercial launch.

American Eagle Outfitters, Inc. is a multi-brand specialty retailer, which offers an assortment of apparel and accessories for men and women under the American Eagle Outfitters brand, and intimates, apparel and personal care products for women under the Aerie brand. The firm operates stores in the United States, Canada, Mexico, Hong Kong, China and the United Kingdom. It also acquired two emerging brands to complement its existing brands, Tailgate, a vintage sports-inspired apparel brand, and Todd Snyder New York, a premium menswear brand. The company was founded in 1977 and is headquartered in Pittsburgh, PA.

American Eagle Outfitters Inc.

American Eagle Outfitters, Inc.

American Eagle Outfitters is trending as investors monitor a massive short interest of over 28 million shares while the stock experiences significant momentum driven by successful marketing campaigns featuring Sydney Sweeney and Travis Kelce. Community discussion is focused on the potential for a short squeeze alongside broader debates about the company's reliance on celebrity-driven retail sales versus macroeconomic pressures on the discretionary sector.

Virtuals Protocol is a launchpad platform launched in 2024 that enables users to create, tokenize, and monetize AI agents for gaming, entertainment, and virtual environments without requiring technical expertise. Initially built on Ethereum's Base Layer 2 network, the protocol has expanded to Ethereum mainnet, Solana, and Ronin as of 2025. VIRTUAL serves as the base liquidity pair and transactional currency for all AI agent interactions across the ecosystem.  The protocol operates through a bonding curve system where new AI agents are created with a 100 VIRTUAL fee. Users can buy and sell agent tokens until the agent reaches 42,000 VIRTUAL, at which point it graduates to a permanent liquidity pool paired with VIRTUAL. AI agents are multimodal, capable of text, speech, and 3D animation, and can manage on-chain wallets autonomously. Notable examples include Luna, an AI girl band vocalist with over 500,000 TikTok followers. The GAME framework powers agent functionality, enabling them to process inputs, generate responses, and remember past interactions.  Virtuals Protocol was founded by Jansen Teng and Weekee Tiew, evolving from PathDAO, a gaming guild established in 2021 that pivoted to AI agents in January 2024. The team raised $16 million in seed funding led by DeFiance Capital and Beam. In 2025, major partnerships were announced with Animoca Brands and a collaboration with Zyfai and BasisOS to launch an Agentic Fund of Funds.  Users can stake VIRTUAL tokens for veVIRTUAL to participate in DAO governance and may receive airdrops of agent tokens. When users interact with agents, they pay fees in VIRTUAL that generate protocol revenue. This revenue funds periodic buybacks and burns of the VIRTUAL token, reducing its total supply as a value-accrual mechanism for holders.

Virtual Protocol

Virtual Protocol is currently a major focus for the AI agent sector, with the community closely tracking potential catalysts like Coinbase listings and broader integration within the Agentic AI narrative. While some traders are expressing frustration over price volatility, the conversation remains heavily centered on long-term accumulation and optimistic projections for the token's role in the expanding AI agent economy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>On Stocktwits, retail chatter jumped about 25% over the past day, with message volume going from ‘normal’ to ‘high’ levels in the time frame.&nbsp;</li><li>Earlier this month, Eastman Kodak reported its fourth-quarter (Q4) 2025 earnings results, posting quarterly revenues of $290 million, a growth of 9%.</li><li>Meanwhile, the company also reduced its annual interest expense by approximately $40 million in FY25, strengthening its balance sheet.</li></ul>Shares of Eastman Kodak Co. (KODK), or Kodak as it is commonly referred to, surged more than 12% on Friday, briefly breaching the $10-mark for the first time since June 2021.The iconic American photography company garnered significant attention among retail traders for the milestone, with some cheering the ‘Kodak’ moment.On Stocktwits, retail chatter jumped about 25% over the past day, with message volume going from ‘normal’ to ‘high’ levels in the time frame.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260327_105336760_png_30e5326fee.webp" alt="koyfin_20260327_105336760.png" width="2400" height="1240"><figcaption>KODK stock price over 5 years | Source: Koyfin</figcaption></figure><h2 class="st-heading-2">&nbsp;</h2><h2 class="st-heading-2">What’s Retail Saying?</h2>Retail sentiment around KODK shares was ‘extremely bullish’ over the past 24 hours.One user touted the share price jump as a ‘Kodak moment’, using a term from the company’s successful advertising campaign.<stembedurl>https://stocktwits.com/DocPharm/message/648774392</stembedurl>&nbsp;Another bullish user cheered the company’s share price ascending to its ‘fair value.’<stembedurl>https://stocktwits.com/Lizzie1/message/648768482</stembedurl>&nbsp;A third user commented on the company’s shares climbing in a down market, while also noting Kodak’s value and strong balance sheet.<stembedurl>https://stocktwits.com/ChicagoMan/message/648637855</stembedurl>&nbsp;A fourth user said KODK shares were ‘still cheap’ despite the company’s recent financial improvement.<stembedurl>https://stocktwits.com/ChicagoMan/message/648768307</stembedurl><h2 class="st-heading-2">&nbsp;</h2><h2 class="st-heading-2">Financial Snapshot</h2>Earlier this month, Eastman Kodak reported its fourth-quarter (Q4) 2025 earnings results, posting quarterly revenues of $290 million, a growth of 9%. The company also posted operational earnings before interest, tax, depreciation, and amortization of $22 million, an increase of 144%.Meanwhile, the company also reduced its annual interest expense by approximately $40 million in FY25, with management adding that Kodak now has a “stronger balance sheet than we’ve had in years.” The company had a cash balance of $337 million as of Dec. 31, 2025, an increase of $136 million from Dec. 31, 2024, with management noting that the company now had more cash than debt.<a href="https://stocktwits.com/symbol/KODK">KODK stock</a> has risen more than 50% in the past year.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/wyfi-stock-tumbles-after-earnings-miss/cZ3HJWFRImB">WYFI Stock Tumbles Nearly 10% After Q4 Earnings Miss — What's Wall Street's Take?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Eastman Kodak Company logo is seen displayed on a smartphone screen.

KODK Stock Crosses $10-Mark For First Time In Nearly 5 Years — Retail Cheers 'Kodak Moment'

Eastman Kodak shares surged more than 12% on Friday, garnering significant attention from retail investors.

Equity

<ul class="summary-bullets"><li>The company said the errors were identified in the consolidated financial statements for the year ended&nbsp;Dec.&nbsp;31, 2024 as well as out-of-period errors for all three quarters of 2025.</li><li>The majority of these errors relate to accounting for revenue, software development costs, and share-based payments.&nbsp;</li><li>TBRG said that the above-mentioned errors did not result in a material misstatement of its previously issued financial statements.</li></ul>TruBridge&nbsp;Inc.&nbsp;(TBRG), a leading provider of healthcare technology solutions for rural and community hospitals, announced on Monday&nbsp;that it has postponed its fourth-quarter (Q4) and year-end 2025 earnings release and conference call.TruBridge said that it requires additional time for the completion of its year-end audit procedures, and was therefore delaying its results previously scheduled for March 16, 2026.The company will issue a separate announcement confirming the date of the release of fourth quarter and year-end 2025 financial results,&nbsp;it said.&nbsp;Shares of the company declined more than 5% after the announcement.&nbsp;<h2 class="st-heading-2">Errors In Accounting</h2>TruBridge said that while conducting final procedures with the preparation of its financial statements for the fiscal year ended&nbsp;Dec. 31, 2025, errors were identified in the consolidated financial statements for the year ended&nbsp;Dec.&nbsp;31, 2024 as well as out-of-period errors in the condensed financial statements for the quarters ended March 31, June 30, and&nbsp;Sept. 30, 2025.The majority of these errors relate to accounting for revenue, software development costs, and share-based payments.&nbsp;TBRG said that the above-mentioned errors did not result in a material misstatement of its previously issued financial statements, and the errors are non-cash in nature, and do not impact company’s operations or liquidity.&nbsp;TruBridge expects to file the 2025 Form 10-K within the 15-day extension period granted by the&nbsp;U.S. Securities and Exchange Commission (SEC), as well as issue its&nbsp;Q4 and year-end 2025 financial results and hold its rescheduled earnings call by March 31, 2026.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around TBRG&nbsp;stock trended in ‘neutral territory’ amid ‘high’ message volume.&nbsp;Shares in the company have fallen 25% so far in 2026.&nbsp;

Shares of TruBridge have fallen 25% so far in 2026. 

Why Has TruBridge Delayed Its Planned Q4 Results?

TruBridge said that it requires additional time for the completion of its year-end audit procedures.

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

CNVS Stock Surged 20% Today, Breaching 100-DMA For First Time Since August – Here’s What Triggered The Rally

The company announced the acquisition of ad-tech firm IndiCue for up to $40 million in total consideration.

<ul class="summary-bullets"><li>Prelude Therapeutics now anticipates dosing the first patient with PRT12396 by the second quarter of 2026.</li><li>The early stage trial will determine the safety, efficacy and pharmacokinetic profile of PRT12396.</li><li>The company said that the FDA’s clearance marks the first milestone in its focus on certain programs that it outlined in the last quarter.</li></ul> Shares of Prelude Therapeutics Incorporated (PRLD) closed 13% higher on Tuesday and edged up 2% after hours after the U.S. Food and Drug Administration (FDA) gave clearances to proceed with early-stage trials for its experimental drug PRT12396.PRT12396 is being developed for the treatment of patients with certain myeloproliferative neoplasms. Myeloproliferative neoplasms (MPNs) are a group of rare, slow-growing blood cancers where the bone marrow produces too many red blood cells, platelets, or certain white blood cells, often due to acquired genetic mutations, leading to symptoms like fatigue, itching, headaches, and bleeding or clotting issues.<h2 class="st-heading-2">Trial Design And Timeline</h2>Prelude Therapeutics <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/03/3231175/0/en/Prelude-Therapeutics-Receives-FDA-Clearance-of-Investigational-New-Drug-Application-IND-for-PRT12396-a-Mutant-selective-JAK2V617F-Inhibitor.html">anticipates</a> dosing the first patient with the drug by the second quarter of 2026. The company said that the FDA’s clearance marks the first milestone in its focus on certain programs that it outlined in the last quarter.“We look forward to advancing PRT12396 into the phase 1 study in patients with polycythemia vera and myelofibrosis in parallel,” said Kris Vaddi, Chief Executive Officer of Prelude. Both polycythemia vera and myelofibrosis are types of blood cancer.The early-stage trial will determine the safety, efficacy and pharmacokinetic profile of PRT12396.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PRLD stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.A Stocktwits user opined that the news might be a hint that the company is moving in the right direction.<stembedurl>https://www.stocktwits.com/Jaybird827/message/643826772</stembedurl>Another voiced optimism for the stock rising as high as $3.<stembedurl>https://www.stocktwits.com/moosegoose/message/643791216</stembedurl><a href="https://stocktwits.com/symbol/PRLD">PRLD stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-shares-garner-retail-attention-ahead-of-q4-earnings-report/cZb02YuR4mN">VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did PRLD Stock Surge 13% Today?

Prelude Therapeutics said on Tuesday that the FDA gave clearances to proceed with early-stage trials for its experimental drug PRT12396. 

<ul class="summary-bullets"><li>Cantor Fitzgerald’s new price target on CABA represents over 1,000% potential upside to the stock’s closing price on Thursday.</li><li>The company said on Monday that data from across trials reinforce the potential of a single weight-based dose of Rese-cel to deliver durable, drug-free clinical responses across multiple autoimmune diseases.</li><li>Rese-cel is an investigational, autologous CAR-T cell therapy explicitly designed for the treatment of autoimmune diseases in rheumatology, neurology, and dermatology. &nbsp;</li></ul>Cantor Fitzgerald on Friday raised its price target on Cabaletta Bio (CABA) to $30 from $15 while keeping an ‘Overweight’ rating on the shares.The new price target represents over 1,000% potential upside to the stock’s closing price on Thursday.According to TheFly, the analyst noted that Auto-CAR-T is showing unprecedented and transformational efficacy in systemic sclerosis, and investors aren't appreciating the substantial unmet need.Scleroderma, also known as systemic sclerosis, is a group of autoimmune diseases that cause the hardening and tightening of the skin and connective tissues, and can also damage blood vessels and internal organs. It is characterized by the excessive buildup of collagen, which leads to fibrosis.<h2 class="st-heading-2">Cabaletta Presents Positive Data</h2>Cabaletta on Monday announced positive clinical data across trials evaluating Rese-cel. Rese-cel is an investigational, autologous CAR-T cell therapy explicitly designed for the treatment of autoimmune diseases in rheumatology, neurology, and dermatology. It is administered as a single, weight-based infusion to reset the immune system and achieve durable clinical responses without the need for chronic therapy.The company said that the data from the trials reinforce the potential of a single weight-based dose of Rese-cel to deliver durable, drug-free clinical responses across multiple autoimmune diseases.“We look forward to initiating the myositis registrational trial and anticipate alignment with FDA on the designs for lupus and systemic sclerosis this year,” said David J. Chang, Chief Medical Officer of Cabaletta, on Monday.While Myositis is a group of rare conditions characterized by muscle inflammation, Lupus is a chronic autoimmune disease where the body's immune system mistakenly attacks healthy tissues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CABA">CABA stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:621/60;" src="data:image/png;base64,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" width="621" height="60" alt="CABA's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Oct. 31, 2025 | Source: Stocktwits"><figcaption>CABA's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Oct. 31, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the company’s pipeline to generate substantial revenue in six years.<stembedurl>https://stocktwits.com/Bronco6970/message/634482351</stembedurl>CABA stock is up by 46% this year but has dropped 7% over the past 12 months. &nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pony-ai-stock-flips-between-gains-and-losses-after-key-shenzhen-permit/cLGqPQKR3U6">Pony AI Stock Flips Between Gains And Losses After Key Shenzhen Permit: Retail Expects Shares ‘Will Run Up In The Future’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cabaletta Bio logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Does Cantor Fitzgerald See Over 1,000% Potential Upside For Cabaletta Bio Stock?

The analyst noted that Auto-CAR-T is showing unprecedented and transformational efficacy in systemic sclerosis, and investors aren't appreciating the substantial unmet need this represents. 

Small-Cap ETFs Rally in July: Will the Momentum Continue?

Small-cap ETFs like AVSC, XSVM, BBSC, SVAL and EES are soaring in July, fueled by rate cut hopes, deep discounts and sector rebounds.


Shares of Corvus Pharmaceuticals, Inc., fell in Tuesday's extended trading hours after the company posted financial results below Wall Street expectations, although retail traders remained optimistic.The pre-revenue biotech posted an adjusted fourth-quarter (Q4) loss of $0.18 per share, steeper than the expected $0.12 loss.&nbsp;Research and development expenses in the reported quarter rose to $6 million from $4 million a year earlier, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.R&amp;D expenses climbed to $19.4 million for the full year from $16.5 million in 2023."We continue to advance our selective ITK inhibitor, soquelitinib, in a range of diseases," said CEO Richard Miller.Preclinical data supports its potential in a range of conditions, including solid tumors, autoimmune disorders such as ALPS and systemic sclerosis, as well as inflammatory diseases like asthma and psoriasis.Corvus is nearing complete enrollment in the third cohort of its Phase 1 atopic dermatitis trial, while its Phase 3 trial in peripheral T-cell lymphoma (PTCL) is enrolling patients across multiple sites.&nbsp;The company recently launched a Phase 2 trial for ALPS and plans to initiate a solid tumor study in the third quarter of 2025.As of Dec. 31, 2024, Corvus held $52 million in cash, cash equivalents, and marketable securities, up from $27.1 million a year ago, which it expects to fund operations into the first quarter of 2026.On Stocktwits, sentiment for Corvus flipped into 'extremely bullish' territory from 'bearish' a day ago, accompanied by a 1,000% spike in message volume.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CRVS_sentiment_and_message_volume_as_of_March_25_png_2347150685.webp" alt="CRVS sentiment and message volume as of March 25.png" width="1318" height="302"><figcaption>CRVS sentiment and message volume as of March 25. | source: Stocktwits</figcaption></figure>One user was bullish after the company's chief executive said the full data for the first three cohorts of its atopic dermatitis trial would be presented at the Society for Investigative Dermatology (SID) Annual Meeting in San Diego in May.<stembedurl>https://stocktwits.com/WalterBean/message/609216709</stembedurl>Another retail watcher expects the stock to close above $4 on Wednesday.<stembedurl>https://stocktwits.com/tradingjunk321/message/609231445</stembedurl>Corvus stock is down more than 28% this year but has more than doubled over the past 12 months. According to Koyfin, out of the six analysts covering the stock on Wall Street, five rate it 'buy' and one rates it 'strong buy.'For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger

Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma. 

Verint Systems, Inc. ($VRNT), a customer experience automation company, announced fiscal year 2025 third-quarter results that exceeded expectations, thanks to strong artificial intelligence (AI) momentum. The company maintained its full-year guidance, sending its shares sharply higher on Thursday.The Melville, New York-based company reported third-quarter non-GAAP earnings per share (EPS) of $0.54, down from the $0.65 earned a year ago but exceeding the consensus estimate of $0.43.Revenue climbed 3% year-over-year to $224 million, above the average analysts’ estimate of $210.13 million. The revenue growth was 5% on a non-GAAP basis, as adjusted for the divestiture of the quality managed services business.Dan Bodner, Verint CEO, said, “We are pleased with our momentum in AI innovation and in customers reporting strong, tangible AI business outcomes with the Verint open platform.”“In Q3, we saw strong demand for AI business outcomes and our bundled SaaS revenue growth accelerated to 19% year-over-year.”Verint said its new software-as-a-service (SaaS) average contract value (ACV) bookings for new deals, excluding cloud conversions, increased 37% YoY in the third quarter.Gross margins expanded 70 basis points YoY due to the mix shift toward recurring revenue.The company maintained its 2025 revenue guidance of $933 million, +/- 2 percentage points and EPS outlook of $2.90. Analysts, on average, estimate the numbers to be $933.26 and $2.91, respectively.Verint also announced its latest AI-powered bot on the Veint platform on Thursday.&nbsp;CFO Grant Highlander said the company will showcase its AI differentiation at the upcoming investor day on January 14.&nbsp;“Investors will hear directly from our customers on AI business outcomes and we will review our financial model, including FYE26 guidance and our long-term model for monetizing AI,” he added.<figure class="image"><img style="aspect-ratio:643/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/vrnt_sentiment_8f1342b2c0.png" alt="vrnt-sentiment.png" width="643" height="137"><figcaption>VRNT sentiment and message volume December 5, 2024, premarket as of 11:26 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Stocktwits users are ‘extremely bullish’ (97/100) toward the stock, with sentiment improving from neutral a day ago. Message volume continues to be ‘extremely high.’At last check, Verint shares climbed 24.53% to $32.34. The stock has lost about 4% this year but has traded in the $21-$38 range.For updates and corrections email newsroom[at]stocktwits[dot]com.

Artificial Intelligence - Chatbot concept in neon style - stock photo

Verint Stock Soars On AI-Fueled Q3 Beat: Retail Sentiment Brightens

Verint highlighted the momentum in AI innovation and customers reporting strong, tangible AI business outcomes with its open platform.

AVSC
American Century ETF Trust - Avantis U.S Small Cap Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest AVSC News

AVSCAmerican Century ETF Trust - Avantis U.S Small Cap Equity ETF